Study of Liver Cancer in Dogs

First in Dog Oncology Trial Utilizing Radioembolization Eye90 microspheres® Advanced Treatment Study (FIDO TREATS)

ABK Biomedical and our partners at The College of Veterinary Medicine, University of Missouri, are recruiting dog patients for a clinical trial evaluating the effectiveness of Y90 radioembolization for the treatment of liver cancer in dogs.

Eye90 microspheres® are currently being studied in humans with liver tumors.

Dogs with liver cancer that meet the full eligibility criteria will receive one radioembolization treatment, and some will be selected for further potentially curative partial liver surgery.

ABK Biomedical will cover the costs of transportation for the pet owner and their pet to and from Columbia, MO for treatment and follow-ups. Pet owners will also receive $2000 towards future veterinary care for their participation in this trial.

Liver cancer in dogs
Liver Cancer in dogs

Study Design and Conduct

Terms of The Study

A full screening will be performed prior to enrollment

Pet owner must be willing to transport their dog to and from the treatment center in Columbia, MO

Treatment includes Y90 radioembolization of hepatocellular carcinoma with Eye90 microspheres®

Treatment will be followed by examination and imaging at 3 months and 6 months

All dogs will receive radioembolization and a subset will be considered for subsequent, liver surgery

Participation may require a total of up to 5-visits over 6-months

Study benefits include:

•Radioembolization and surgical resection (if eligible)
•Follow-up physical exams and CT imaging at 3- and 6- months
•The opportunity to contribute to the development of an important cancer therapy for dogs with liver cancer

Eligibility Criteria

Any type of dog diagnosed with liver cancer is potentially eligible for study entry.

Candidates must also meet all the following requirements:

  • Signed informed consent from the client prior to any study-related evaluation
  • Be neutered or spayed
  • At least one liver tumor must be great or equal to 2cm diameter,  with no more than 3 tumors total
  • Be a minimum of 9kg (19.8lb)
  • Be more than 1 year old
  • Have a reasonable life expectancy of more than 3 months without treatment
  • Have pathology confirmed hepatocellular carcinoma and no other diseases or behavioral conditions that would interfere with study conduct

Background and Rationale

Radiation therapy uses high-energy radiation to shrink tumors and kill cancer cells. The radiation is intended to damage the DNA of the cancer cells beyond repair so that they stop dividing or die. Radioembolization with Y90 is an advanced form of radiation therapy that delivers high-dose radiation with precision, enabling precise targeting of a tumor with minimal damage to nearby healthy tissue.

Y90 has been used to successfully treat liver tumors in over 100,000 human patients.  Studies have revealed that Y90 is well-tolerated by the patient, results in minimal complications or side effects, maintains or improves the quality of life, and results in equivalent survival times when compared to surgery for patients with operable tumors.

Eye90 microspheres® are currently being studied in humans with liver tumors.

Study Design

This is a two-arm prospective study. At least 6 dogs with liver cancer are planned for enrollment. 

Arm 1: Eye90 microspheres®

Arm 2: Eye90 microspheres® plus partial-liver surgical resection

Eligible patients will be treated once with Y90 under a protocol consistent with the quality assurance practices of The College of Veterinary Medicine, University of Missouri.

Further Information

If you have additional questions about the liver cancer in dogs study please contact the Principal Investigator at the address below, or click the link to send an Email:

Jeffrey N. Bryan, DVM
Professor of Oncology

Veterinary Medicine & Surgery
University of Missouri
Columbia, MO  65211

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3

T. 902.442.4009


Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved